Bexarotene Treatment in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00141947
Recruitment Status : Unknown
Verified October 2005 by Vladimir Lerner, Beersheva Mental Health Center.
Recruitment status was:  Recruiting
First Posted : September 2, 2005
Last Update Posted : July 24, 2013
Stanley Medical Research Institute
Information provided by (Responsible Party):
Vladimir Lerner, Beersheva Mental Health Center

Brief Summary:
In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069; 4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) on severity of psychopathology, cognitive impairment, and quality of life in schizophrenia patients in an open label trial. The rationale behind add-on oral bexarotene to ongoing antipsychotic treatment in schizophrenia patients is based on both the retinoid dysregulation hypothesis (Goodman, 1995) and the growth factors deficiency and synaptic destabilization hypothesis (Moises et al, 2002) of schizophrenia. In this clinical trial, a novel regimen of low dose bexarotene (Targretin, 75 mg/day) will be added for 6 weeks to the standard treatment of 15 schizophrenia patients on stable antipsychotic treatment. Participants will be assessed at baseline and after 2, 4 and 6 weeks of treatment. A battery of research instruments will be used for assessment of efficacy and safety (psychopathology, and side effects). In addition, cholesterol and triglyceride levels, liver and thyroid function tests and a blood cell count will be monitored at baseline and during therapy.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: bexarotene (Targretin) Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Add-On Oral Bexarotene to Antipsychotic Treatment in Schizophrenia Patients: An Open Label Trial
Study Start Date : September 2005
Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
Drug Information available for: Bexarotene
U.S. FDA Resources

Primary Outcome Measures :
  1. Schedule for Assessment of Mental Disorder
  2. The Positive and Negative Syndrome Scale
  3. Montgomery and Äsberg Depression Rating Scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18-60
  • schizophrenia
  • stable blood parameters
  • normal baseline fasting triglyceride
  • ability to sign informed consent

Exclusion Criteria:

  • lipid abnormalities
  • leukopenia or neutropenia
  • organic brain damage (mental retardation)
  • alcohol or drug abuse
  • renal disease
  • hepatic dysfunction
  • history of pancreatitis
  • thyroid axis alterations
  • suicide attempt in past year
  • cataracts
  • systemic treatment with more than 15,000IU vitamin A daily
  • patients with known hypersensitivity to bexarotene or other components of the product
  • pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00141947

Contact: Vladimir Lerner, MD, PhD 972-8-6401408
Contact: Chanoch Midownik, MD 972-8-6401404

Beersheva Mental Health Center Recruiting
Beersheva, Israel
Contact: Vladimir Lerner, MD, PhD    972-8-6401408   
Principal Investigator: Vladimir Lerner, MD, PhD         
Shaar Manashe Mental Health Center Recruiting
Hadera, Israel
Contact: Michael Ritsner, MD    9728-627-8750   
Principal Investigator: Michael Ritsner, MD         
Sponsors and Collaborators
Beersheva Mental Health Center
Stanley Medical Research Institute
Principal Investigator: Vladimir Lerner, MD, PhD Ben-Gurion University of the Negev
Principal Investigator: Michael Ritsner, MD Technion-Israel Institute of Technology (Haifa)

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Vladimir Lerner, Associated Professor, Beersheva Mental Health Center Identifier: NCT00141947     History of Changes
Other Study ID Numbers: BMHC-3775
First Posted: September 2, 2005    Key Record Dates
Last Update Posted: July 24, 2013
Last Verified: October 2005

Keywords provided by Vladimir Lerner, Beersheva Mental Health Center:
cognitive impairment
quality of life
open lable trial

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents